Effects of physical training on coagulation parameters, interleukin-6, and angiotensin-converting enzyme-2 in COVID-19 survivors

Abstract

COVID-19 is a highly contagious virus that uses Angiotensin-converting enzyme 2 (ACE2) as a receptor to enter human cells. The virus leads to an increase in inflammatory cytokines (i.e. IL-6) and an impaired coagulation system, which can cause serious complications during and after the disease. Physical exercise has been shown to improve COVID-19 complications through various mechanisms, such as modulation of the immune and coagulation systems. Therefore, this study investigated the effects of 8 weeks of training on inflammatory, coagulation, and physical factors in patients with COVID-19 during the recovery phase. Twenty-seven male and female volunteers (age 20–45 years) who recently recovered from COVID-19 were assigned to the control (n = 13) or the training group (n = 14). Blood samples, aerobic capacity and muscle endurance were collected 24 h before the start of the interventions and 24 h after the final training session in week 4 and 48 h after the final training session in week 8. IL-6, ACE2, fibrinogen, and D-dimer were measured using ELISA. The training group showed a significant increase in muscle endurance (p = 0.004) and aerobic capacity (p = 0.009) compared to the control group. Serum levels of IL-6 and fibrinogen decreased in the training group but this decrease was not statistically significant (p > 0.05). Despite a slight increase in the quality of life and sleep in the training group, no statistically significant difference was observed between the training and the control group. It appears that physical training has beneficial effects on the coagulation system, inflammatory factors, and sleep quality and can facilitate the recovery of COVID-19 patients.

Introduction

Coronavirus is classified in the Orthocoronavirinae subfamily of the Coronaviridae family¹. In late 2019, a new coronavirus (SARS-CoV-2) was discovered in Wuhan, Hubei, China, which caused respiratory illness. This disease was named Coronavirus Disease 2019 or COVID-19. Infection by SARS-CoV-2 changes the binding of host cells to the angiotensin-converting enzyme-2 (ACE2), which is the virus's receptor². The spike protein of SARS-CoV-2 identifies ACE2 receptors on host cells, resulting in the virus fusing with them³. The ACE2 protein is expressed in multiple organs, such as the heart, kidneys, adrenal glands, pancreas, and skeletal muscle, as well as arterial and venous endothelial cells and arterial smooth muscle cells^4,5. Recent studies have that when ACE2 expression was decreased, the virus was less likely to infect mice^6,7. Accordingly, ACE2 may contribute to COVID-19 pathophysiology⁸.

COVID-19 is a self-limiting infection in which the host's immune system plays an important role in the defense response⁹. To control viral replication and inflammation, effective antiviral responses from the host's innate and adaptive defenses, including the generation of numerous pro-inflammatory cytokines and the activation of T cells, are necessary¹⁰. Following exposure to COVID-19 and the occurrence of cytokine storms, the blood levels of pro-inflammatory cytokines increase^11,12. Among the excessive cytokines generated by activated macrophages, IL-6 is one of the main cytokines¹³. IL-6 is a cytokine with multiple functions, involved in both pro- and anti-inflammatory processes^14–16. Elevated levels of IL-6 were consistently found in several studies, suggesting that it could be used as a biomarker to predict disease severity^17–19.COVID-19 can also be associated with thrombogenic coagulopathy, with a variety of manifestations. SARS-CoV-2 directly invades the endothelial cells with ACE2 receptors, constituting the main pathway through which the virus enters these cells. This invasion causes angiotensin II accumulation and downregulation of the ACE2 receptors, resulting in prothrombotic effects such as hemostatic imbalance via activation of the coagulation cascade, impaired fibrinolysis, thrombin generation, vasoconstriction, endothelial and platelet activation, and pro-inflammatory cytokine release.²⁰ Thus, coagulopathy is associated with a higher death rate in COVID-19 patients^21,22. While clinical biomarkers are still required to predict disease severity, hematological markers such as D-dimer and fibrinogen have been shown to correlate with the presence of coagulopathy in COVID-19^23,24. D-dimer is widely used in clinical settings as a biomarker of endogenous fibrin clot formation and a recognized laboratory indicator of hypercoagulability^25,26. COVID-19 patients with higher D-dimer levels are at higher risk of intensive care unit admission or even death^27,28. One of the most precise tests for diagnosing disseminated intravascular coagulation (DIC) is fibrinogen concentration²⁹. The mean fibrinogen concentrations in COVID-19 patients were found to be above the normal range³⁰. Thus, these two hematological factors have the potential to be a promising marker for monitoring COVID-19 patients during and after treatment.

While millions of individuals were quarantined during the COVID-19 outbreak, the sedentary behaviour and increase in health disorders caused by the quarantine might have impacted their overall health and quality of life^31,32. Studies investigating the association between physical activity (PA) and the risk of COVID-19 infection are currently scarce. However, several studies have reported a positive impact of regular physical activity on comorbidities associated with severe COVID-19^33,34. Emerging evidence suggests that an active lifestyle is the best choice for good health and that physical exercise is an effective non-pharmacological intervention for many chronic diseases, including COVID-19³⁵. Studies have shown that those who are physically active have a reduced incidence, severity of symptoms, and morbidity from viral infections³⁶. Additionally, it has been reported that exercise can improve risk factors for severe COVID-19³⁷.

Regular exercise improves cardiorespiratory health, strengthens muscles, and reduces the risk of systemic inflammation, which are the processes by which it reduces the symptoms of various acute and chronic morbidities³⁸. Physical exercise appears to have a significant impact on the immune and coagulation systems in patients diagnosed with COVID-19^36,39,40. In this regard, it has been documented that long-duration or high-intensity exercises (above 80% VO₂max) result in immunosuppression markers, which are accompanied by an elevation in pro-inflammatory cytokines (e.g., IL-6 and TNF-α). As a result, individuals with infectious diseases like COVID-19 are at a greater risk of infection^41,42. Regular physical activity has decreased by 9–48% in response to self-isolating instructions to slow COVID-19 outbreak⁴⁰. COVID-19 patients often experience decreased physical activity due to venous thromboembolism, which can involve pulmonary embolism or deep vein thrombosis^43–47.

With the initial activation of the immune system upon infection with SARS-CoV-2, the clotting pathway also becomes activated, which has been termed the thrombi-inflammatory state⁴⁸. The coronavirus decreases ACE2 activity by deregulating the renin–angiotensin–aldosterone system (RAAS). As a consequence, angiotensin II is not converted and remains active in prothrombotic and inflammatory processes⁴⁹. In response to abnormal tissue factors, primarily caused by IL-6 and also by the complement factor C5a, vessel walls are disrupted, resulting in thrombin, fibrinogen, and fibrin production. In addition to activating fibrin and fibrinogen, thrombin and coagulation factor X boosts the immune response by producing more inflammatory cytokines. COVID-19 has a thrombi-inflammation state, which can be confirmed by the presence of IL-6, D-dimer, and fibrinogen. The thrombosis leads to both microvascular thrombosis and multiple organ dysfunction syndromes^48,50,51.

Considering the severe impact of COVID-19 and the limitations in accessing information about the recovery rate of COVID-19 patients, a detailed and comprehensive rehabilitation program with individual exercise protocols will be useful for patients with long-term COVID-19 to restore a level of physical fitness comparable to the initial level before the disease⁵². This study aimed to evaluate the effects of training on IL-6, ACE-2, D-dimer, and fibrinogen in COVID-19 survivors. We hypothesized that 8 weeks of exercise during the recovery period can positively affect the coagulation parameters, interleukin-6, and angiotensin-converting enzyme-2 who have recovered from COVID-19.

Methods

Subjects

This study was a semi-quasi study with a pre and post-test design. The sample size required for this study was calculated using G*Power version 3.1.9.6⁵³. With a repeated measures analysis of variance (ANOVA), a rejection criterion of 0.05, a power of 0.8, and a large effect size (f = 0.6), at least twenty participants were required to achieve the above criterion.

The participants of the current study, twenty-seven individuals (age 20–45 years) who had recovered from COVID-19, were matched based on the severity of their condition and randomly assigned to the training (6 men and 8 women) or the control group (8 men and 5 women). This project was conducted at the Nabie-Akram Clinical Institution, in Bushehr, Iran. Patients with COVID-19, diagnosed according to WHO interim guidance, and 10 to 30 days after a positive COVID-19 PCR test, were eligible to participate in this study. The supervising physician evaluated the severity of their condition and only participants with low to moderate levels of illness were eligible to participate. The extent of lung involvement at the start of the study was very mild or mild, as determined by clinical examinations and recorded by the supervising physician.

Patients who had a history of diabetes, heart disease, cancer, drug misuse or dependency, or high blood pressure were not eligible to participate in the study. To comply with ethical considerations, ensure the confidence of the participants, and observe safety precautions, all sessions were conducted in the presence of a supervising physician.

The exercise protocol was implemented following health guidelines, which included wearing masks and maintaining social distancing. The exercise protocol implementation site and used equipment were thoroughly disinfected before and after each session. Additionally, the training facility was well-ventilated. All blood sampling procedures were performed in a research laboratory by a qualified phlebotomist under all legal regulations. The risks and benefits of the study were explained to all participants and they signed a written informed consent form in accordance with the Declaration of Helsinki. Participants were informed about the voluntary nature of the study and were allowed to withdraw from the study at any time. In addition, the Ethics Committee of the Research Institute of Physical Education and Sports Sciences reviewed and approved the study.

Training protocol

Training was performed three times per week for 60 min in a well-equipped gymnasium in Bushehr. A summary of the training protocol from week 0 to week 8 is shown in Tables 1 and 2. Table 1 details the exercises for weeks 0–4, and Table 2 details the exercises for weeks 5–8. To prevent training boredom among participants and to offer training variations, each period consisted of two training plans that were applied alternately. These programs were developed based on two pilot sessions in which 5 participants attended. The intensity of the exercises was established based on the feedback from the pilot group and deemed appropriate for the patients in this study. Participants received between 60 and 90 s of rest between each set which appeared to be adequate recovery. A physician examined the subjects before each training session and assessed their vital signs to ensure that the training intensity did not surpass their capacity and did not cause any adverse effects.

Table 1.

Exercise program for week 0 to week 4.

Plan A				Plan B
Exercise	Set	Time/rep	RPE	Exercise	Set	Time/rep	RPE
Jogging in place + Running to the sides Knee back + Running to the sides Knee up + Running to the sides Jumping jacks + Running to the sides Running to the sides with a sign	3 3 3 3	30 s 30 s 30 s 30 s	3–5	Step up/step down Step front kick side Step up/step down Step knee up Step up/step down Step back kick side Step up/step down Step side to side Step up/step down Step jump squat	1	10 min	3–5
Step single leg db in hand	3	60 s	3–5	Swiss ball plank	3	30 s	3–5
Lunges Swiss ball in hand	3	30 s	3–5	Step single leg and take a tennis ball	3	60 s	3–5
Touch a specific color on the wall as soon as you hear the whistle	3	30	3–5	Small steps with space for the ball	3	30 s	3–5
Dumbbell curl + hummer curl Sumo squat dumbbell Lateral raise db + front raise db Push up	3	10 + 10 10 10 + 10 10	3–5	Dumbbell curl + hummer curl Sumo squat dumbbell Lateral raise db + front raise db Push up	3	10 + 10 10 10 + 10 10	3–5
				plank Reverse crunch	3	30 s 30 s	3–5

* db = Dumbbell.

Table 2.

Exercise program for week 5 to week 8.

Plan A				Plan B
Exercise	Set	Time/rep	RPE	Exercise	Set	Time/rep	RPE
Bench press db  + fly db on Swiss ball	3	12  + 12	4–7	Step up/step down Step knee up ankle touch Step side knee up Step up/step down Step plank jacks Jump jacks + jump on step Step climber Step toe taps	1	10 min	4–7
Db curl + shoulder press db	3	12 + 12	4–7	One leg hops	3	30 s	4–7
Lunges side/front	3	12	4–7	Gym ball walk	2	30 s	4–7
Front raise plate + standing chest press plate	3	12 + 12	4–7	Push up while your foot is on the Swiss ball and change it	2	30 s	4–7
Bent row db	3	12	4–7	Gym ball walk	2	30 s	4–7
Db glute bridge	3	12	4–7	Knee up to knee back	3	30 s	4–7
Front raise db + lateral raise db	3	12 + 12	4–7	Speed running 4 × 10 m	3		4–7
Overhead triceps extension db	3	12	4–7	Touch partner around the circle	3		4–7
Deep squat db + calf raise	3	12 + 12	4–7	Basic crunch Flutter kick Half wipers Tuck crunch Side plank	3 3 3 3 3	12 12 12 12 12	4–7

*db = Dumbbell.

Blood collection and analysis

Blood samples were collected after 8–10 h of overnight fasting from the median cubital vein 24 h before the beginning of the intervention, and 24 h after the last training session in week 4 and 48 h after the last training session in week 8. The samples were centrifuged for 10 min at 3000 RPM. The serum was separated and kept at -80°C until further analysis. Blood variables were measured using ELISA kits (Zell Bio GmbH, Germany). The analyses were performed by following the instruction of the manufacturer of the following kits: Fibrinogen (cat no:ZB-12006C-H9648), IL-6 (cat no:ZB-10090C-H9648), ACE-2 (cat no:ZB-13169C-H9648), and D-dimer (cat no:ZB-09049C-H9648). The sensitivity ranges of the kits were as follows: fibrinogen (0.08 mg/ml), IL-6 (3–5 pg/ml), ACE2 (0.5 ng/ml), and D-Dimer (1–3 ng/ml) were measured in blood serum using an ELISA kit (Zell Bio GmbH, Germany).

Aerobic capacity

All performance tests were administered 24 h before the first training session, 24 h after the last training session in week 4, and 48 h after the last training session in week 8. The Queens College Step Test was used to estimate the subjects' aerobic capacity. The participants stepped on and off a 41.3 cm box at a rate of 24 steps per minute (men) and 22 steps per minute (women) for 3 min. Afterward, the participants stood until their heart rate was recorded for 15 s between the 5th and 20th seconds of the return to baseline. The following VO₂max formula was used to estimate their aerobic capacity⁵⁴:

$${\text{VO}}_2\text{max}\left({\text{mlkg}}^{-1}{\text{min}}^{-1}\right)=111.33-(0.42\times \text{step test pulse rate in beats per minute})$$

Muscle endurance

A push-up test was performed to assess muscle endurance. Participants positioned their hands and toes on the ground in a plank position. Female participants performed modified push-ups, placing their knees on the ground instead of their toes. While performing a controlled contraction, participants lowered their chest close to the ground, then extended their elbows to return to the starting position. The number of push-ups performed until failure was recorded.

Assessment of sleep quality

The Petersburg Sleep Quality Index (PSQI) was used to assess sleep quality⁵⁵. PSQI is a validated tool consisting of 19 questions in seven sections: subjective sleep quality (C1), sleep latency (C2), sleep duration (C3), habitual sleep efficiency (C4), sleep disturbance (C5), use of sedative medications (C6), and daytime dysfunction C7). Each component is given a score that ranges from 0 to 3. Scores of 0, 1, 2, and 3 on each scale indicate normal, slight problems, average problems, and severe problems, respectively. The overall score is then calculated totaling seven component scores, where lower scores denote better sleep quality.

The quality of life

To measure the quality of life among participants in this study, the WHOQOL-BREF questionnaire was employed. The WHOQOL-BREF questionnaire consists of 26 items and assesses four domains: physical health (7 questions), psychological health (6 questions), social relationships (3 questions), and the environment (8 questions)⁵⁶. The first two questions are not relevant to these domains and are only intended to evaluate health and quality of life in general. Thus, there were 26 questions in this survey. The score in each domain ranges from 4 to 20, with 4 and 20 representing the worst and best conditions in each respective domain. Finally, the subjects received a score between 0 and 100⁵⁷.

Statistical analysis

The statistical package for the social sciences (SPSS) was used to analyze the data. The central tendency and dispersion of the data are reported as the mean and standard deviation (SD). A Shapiro–Wilk test was used to determine the normal distribution of the data. A series of mixed model repeated measures analysis of variance (ANOVA) were executed to determine the effects of condition and time on dependent variables. The level of statistical significance was set at 0.05 for all analyses.

Ethics approval and consent to participate

All procedures in this study were carried out under the Helsinki Statement regarding human research. The proposal for this project was presented to the Ethics Committee of the Research Institute of Physical Education and Sports Sciences of Iran and approved (IR.SSRC.REC.1400.041). Also, participants signed an informed consent form prior to participation in the study.

Results

The hematological indices at week 0, week 4, and week 8 are presented in Table 3. A statistically significant time and group interaction was observed in white blood cells, Eosinophil and Eosinophil % (p < 0.05). Additionally, there was a significant time effect on red blood cells, hemoglobin, hematocrit, Mean Corpuscular Volume, Mean Corpuscular Hemoglobin, Red Cell Distribution Width standard deviation, platelets, plateletcrit, monocyte, Eosinophil%, Monocyte, and Eosinophil (p < 0.05). The only group effect was observed in Eosinophil% (p < 0.05). The changes observed in all other variables did not reach the level of statistical significance (p > 0.05).

Table 3.

Hematology results in the training and control groups of COVID-19 patients.

Variables	Groups	Week 0	Week 4	Week 8	Time p-value	Group p-value	Interaction (Time*group) p-value
WBC (/uL)	Training	7535.71 ± 2378.302	6681.43 ± 1975.59	6842.86 ± 1931.80	0.154	0.850	0.027*
	Control	6838.46 ± 1014.51	7284.62 ± 805.03	6600.00 ± 1249.00
RBC (10*6/uL)	Training	4.53 ± 0.75	4.62 ± 0.66	4.75 ± 0.65	0.019*	0.994	0.755
	Control	4.55 ± 0.63	4.63 ± 0.66	4.71 ± 0.73
Hemoglobin (g/dL)	Training	12.04 ± 1.21	12.06 ± 1.21	13.12 ± 1.48	0.000*	0.997	0.466
	Control	11.90 ± 1.11	12.18 ± 1.02	13.13 ± 1.01
Hematocrit (%)	Training	35.17 ± 3.75	35.64 ± 3.59	39.14 ± 4.19	0.000*	0.592	0.931
	Control	35.75 ± 2.79	36.40 ± 2.45	39.72 ± 2.28
MCV (fl)	Training	78.49 ± 7.78	77.84 ± 7.48	82.82 ± 7.68	0.000*	0.667	0.577
	Control	79.51 ± 9.20	79.46 ± 8.94	84.42 ± 9.82
MCH (pg)	Training	27.03 ± 3.80	26.36 ± 2.78	27.91 ± 3.05	0.000*	1.000	0.258
	Control	26.47 ± 3.54	26.63 ± 3.53	28.20 ± 3.77
MCHC (g/dL)	Training	34.35 ± 2.42	33.85 ± 0.65	33.54 ± 0.94	0.150	0.118	0.326
	Control	33.23 ± 0.99	33.43 ± 1.01	33.03 ± 1.22
RDWCV (%)	Training	13.00 ± 0.86	12.88 ± 0.87	12.77 ± 0.78	0.261	0.858	0.319
	Control	13.00 ± 1.19	12.85 ± 1.00	12.99 ± 0.94
RDWSD (fl)	Training	42.31 ± 3.54	41.85 ± 3.13	44.21 ± 3.30	0.000*	0.427	0.466
	Control	43.16 ± 4.41	42.70 ± 3.29	45.69 ± 3.37
Platelet (/uL)	Training	239,214.29 ± 66,581.56	273,500.00 ± 52,779.29	289,714.29 ± 56,360.69	0.000*	0.201	0.415
	Control	276,384.62 ± 60,151.94	297,615.38 ± 55,585.57	308,692.31 ± 50,042.29
MPV (fl)	Training	9.71 ± 1.17	9.32 ± 0.80	9.57 ± 0.74	0.125	0.133	0.191
	Control	8.98 ± 0.64	9.00 ± 0.90	9.24 ± 0.76
PDW	Training	16.19 ± 0.41	16.18 ± 0.34	16.14 ± 0.36	0.700	0.211	0.886
	Control	16.06 ± 0.35	16.02 ± 0.22	16.02 ± 0.26
PCT (%)	Training	0.22 ± 0.05	0.25 ± 0.04	0.27 ± 0.04	0.000*	0.437	0.581
	Control	0.24 ± 0.05	0.26 ± 0.04	0.28 ± 0.04
Neutrophil (%)	Training	56.57 ± 6.60	56.65 ± 7.32	58.24 ± 5.17	0.396	0.552	0.673
	Control	57.26 ± 6.05	59.10 ± 6.50	58.82 ± 6.50
Lymphocyte (%)	Training	33.16 ± 6.33	34.80 ± 7.20	32.88 ± 4.58	0.991	0.344	0.171
	Control	32.04 ± 6.21	30.48 ± 6.47	32.13 ± 6.99
Monocyte (%)	Training	7.20 ± 2.08	6.47 ± 2.17	6.70 ± 1.48	0.022*	0.604	0.623
	Control	7.68 ± 2.03	6.95 ± 1.77	6.75 ± 1.66
Eosinophil (%)	Training	2.72 ± 1.37	1.65 ± 1.28	1.86 ± 0.85	0.029*	0.240	0.006*
	Control	2.53 ± 1.51	3.20 ± 1.57	1.92 ± 0.99
Basophil (%)	Training	0.329 ± 0.126	0.421 ± 0.162	0.343 ± 0.128	0.147	0.027*	0.193
	Control	0.492 ± 0.144	0.485 ± 0.162	0.462 ± 0.180
Neutrophil (10*3/uL)	Training	4.32 ± 1.66	3.81 ± 1.36	4.07 ± 1.07	0.817	0.984	0.059
	Control	3.92 ± 0.86	4.39 ± 0.85	3.92 ± 1.15
Lymphocyte (10*3/uL)	Training	2.46 ± 0.80	2.30 ± 0.76	2.23 ± 0.73	0.177	0.441	0.296
	Control	2.15 ± 0.38	2.21 ± 0.44	2.09 ± 0.38
Monocyte (10*3/uL)	Training	0.523 ± 0.160	0.420 ± 0.172	0.465 ± 0.148	0.020*	0.613	0.058
	Control	0.521 ± 0.145	0.512 ± 0.143	0.458 ± 0.153
Eosinophil (10*3/uL)	Training	0.203 ± 0.126	0.110 ± 0.112	0.129 ± 0.078	0.005*	0.397	0.000*
	Control	0.176 ± 0.133	0.226 ± 0.108	0.130 ± 0.078
Basophil (10*3/uL)	Training	0.021 ± 0.010	0.026 ± 0.014	0.021 ± 0.011	0.443	0.059	0.379
	Control	0.030 ± 0.010	0.035 ± 0.010	0.049 ± 0.076

WBC (White Blood Cells); RBC (Red Blood Cell); MCV (Mean Corpuscular Volume); MCH (Mean Corpuscular Hemoglobin); MCHC (Mean Cell Hemoglobin Concentration); RDWCV (Red Cell Distribution Width Coefficient of Variation), RDWSD (Red Cell Distribution Width standard deviation); MPV (Mean Platelet Volume); PDW (Platelet Distribution Width); PCT (Plateletcrit).

Anthropometric indices are presented in Table 4. There was a significant interaction effect on WHR, and similarly, there was a significant time effect on BMI (p < 0.05). The changes in all other variables did not reach levels of statistical significance (p > 0.05).

Table 4.

Anthropometric results in the training and control groups of COVID-19 patients.

Variables	Group	Week 0	Week 4	Week 8	Time p-value	Group p-value	Interaction (Time*group) p-value
TBW (L)	Training	35.80 ± 7.47	36.18 ± 7.98	36.13 ± 7.91	0.226	0.158	0.635
	Control	40.60 ± 9.18	40.69 ± 9.03	40.93 ± 8.89
Protein (kg)	Training	9.65 ± 2.07	9.50 ± 2.32	9.75 ± 2.18	0.332	0.144	0.489
	Control	10.92 ± 2.50	10.97 ± 2.44	11.02 ± 2.41
Mineral (kg)	Training	3.37 ± 0.61	3.42 ± 0.66	3.42 ± 0.63	0.220	0.112	0.755
	Control	3.86 ± 0.89	3.87 ± 0.85	3.91 ± 0.85
BFM (kg)	Training	21.65 ± 5.71	21.55 ± 5.52	21.46 ± 5.64	0.365	0.067	0.108
	Control	26.90 ± 9.64	27.33 ± 9.62	27.72 ± 9.75
SMM (kg)	Training	27.07 ± 6.23	27.36 ± 6.58	27.37 ± 6.54	0.170	0.163	0.842
	Control	30.93 ± 7.51	31.10 ± 7.34	31.23 ± 7.25
PBF (%)	Training	31.09 ± 8.13	30.80 ± 8.14	30.69 ± 8.07	0.993	0.561	0.362
	Control	32.41 ± 8.25	32.69 ± 7.44	32.84 ± 7.45
VF	Training	9.50 ± 3.32	9.21 ± 3.09	9.14 ± 3.15	0.563	0.123	0.072
	Control	11.69 ± 5.05	11.69 ± 4.75	12.00 ± 4.91
WHR	Training	0.899 ± 0.039	0.875 ± 0.051	0.878 ± 0.041	0.437	0.056	0.000*
	Control	0.914 ± 0.064	0.926 ± 0.055	0.929 ± 0.060
BMI (kg/m2)	Training	25.41 ± 1.75	26.62 ± 1.68	25.53 ± 1.68	0.021*	0.072	0.069
	Control	27.56 ± 4.01	27.74 ± 4.08	27.9 ± 4.14

TBW (Total Body Water); BFM (Body Fat Mass); SMM (Skeletal Muscle Mass); PBF (Percent Body Fat); VF (Visceral Fat); WHR (Waist Hip Ratio); BMI (Body Mass Index).

The D-Dimer levels for both groups are presented in Fig. 1. There was no significant interaction effect F (2, 50) = 2.545, p = 0.089, group F (1, 25) = 1.700, p = 0.204, or time F (2, 50) = 0.629, p = 0.537.

Figure 1.

The level of D-dimer in the training and the control group.

The circulatory levels of fibrinogen are presented in Fig. 2. There was a significant effect of time F (2, 50) = 11.130, p < 0.001. However, there was no significant interaction effect F (2, 50) = 0.705, p = 0.499, or group F (1, 25) = 0.987, p = 0.330.

Figure 2.

The level of fibrinogen in the training and the control group.

The plasma levels of IL-6 are presented in Fig. 3. There was a significant effect of group F (1, 25) = 6.496, p = 0.017 and time F (2, 50) = 8.733, p = 0.001. However, the interaction effect did not reach statistical significance F (2, 50) = 2.433, p = 0.098.

Figure 3.

The level of plasma IL-6 in the training and the control group.

The levels of ACE2 for the training and the control group are presented in Fig. 4. There was a significant effect of group F (1, 25) = 8.830, p = 0.006. However, the interaction effect F (2, 50) = 0.231, p = 0.794 and time effect F (2, 50) = 0.075, p = 0.928 were not statistically significant.

Figure 4.

The level of ACE2 in week 4 and week 8 relative to week 0 in the training and control groups.

The quality of life and the sleep quality were measured in week 0, week 4 and week 8 and the results are presented in Table 5. The Quality of Life was not statistically different between the two groups across time. However, the sleep quality improved significantly across time F (2, 50) = 4.705, p = 0.013. The interaction effect F (2, 50) = 0.730, p = 0.487, and the group effect F (1, 25) = 0.024, p = 0.878 on sleep quality was not statistically significant.

Table 5.

Quality of life and sleep quality results in the training and control groups in week 0, week 4, and week 8.

Variables	Group	Week 0	Week 4	Week 8	Time p-value	Group p-value	Interaction (Time*group) p-value
Sleep quality	Training	4.86 ± 1.51	4.50 ± 2.73	3.21 ± 1.52	0.013	0.878	0.487
	Control	4.46 ± 2.02	4.15 ± 1.72	3.69 ± 1.60
Quality of life	Training	83.71 ± 14.93	83.21 ± 13.42	84.86 ± 15.04	0.087	0.450	0.492
	Control	87.00 ± 8.74	84.77 ± 8.09	90.15 ± 12.03

Discussion

This study investigated the effects of 8 weeks of physical training on coagulation parameters, IL-6, and ACE2 in patients who had recovered from COVID-19. The findings indicate that performing low-intensity training during recovery from COVID-19 improves aerobic capacity and muscle endurance, reduces serum levels of IL-6 and fibrinogen and, increases D-dimer. Therefore, our hypothesis was confirmed that physical training can mitigate the negative effects of COVID-19, lower inflammatory and fibrinogen indices, and improve the quality of life for patients by enhancing the recovery process.

After infection, ACE2 plays a regulatory role in the immune response and cytokine secretion⁵⁸. COVID-19 is a highly infectious virus that uses ACE2 as a receptor to enter cells. After entering the body, the virus increases inflammatory cytokines. IL-6, an inflammatory factor, has been reported to remain elevated in the body for a long time after infection, causing physical dysfunction even in patients who have recovered^59,60. Therefore, reducing inflammatory markers such as IL-6 is considered an appropriate therapeutic target for the treatment of viral infections, including COVID-19. Our results showed that the serum level of IL-6 decreased significantly in the training group (47%) compared to the control group (15%). This inverse relationship between physical training and IL-6 levels has already been established and regular exercise reduces the circulatory level of IL-6⁶¹. Additionally, the body fat percentage and waist-to-hip ratio in the training group showed a significant decrease compared to the control group, indicating the effect of exercises on reducing fat tissue. An increase in white adipose tissue can increase serum IL-6⁶²; therefore, exercise may lower inflammatory indicators by reducing fat tissue.

Our data also indicated that serum levels of ACE2 in the training group did not show a significant difference compared to the control group. Increased serum ACE2 level in COVID patients could indicate poor prognosis and is linked to various diseases that increase angiotensin-renin system activity⁶². Coronavirus decreases membrane activity by damaging membrane ACE2, resulting in thrombosis by increasing vascular permeability and expressing tissue factors in leukocytes and platelets^63,64.

Numerous studies have examined the impact of physical activity on inflammatory factors and the immune system. The results demonstrated that regular exercise may have an anti-inflammatory effect on the body in certain diseases, such as COVID-19^65,66. Given the benefits of physical activity in reducing the risks of various diseases, it can be assumed that active individuals have better control over high-risk comorbidities that increase their susceptibility to severe COVID-19 compared to sedentary people. However, some studies have reported different roles of physical activity in COVID-19 patients. While moderate-intensity exercise is beneficial for the immune system, prolonged and high intensity exercise can suppress the immune system by disrupting the balance of cytokines type I and II, which may increase the risk of infection. The effects of physical activity on ACE2 receptor modulation have been established, but clinical implications for angiotensin-related pathways in humans are still unclear^67,68.

The accumulation of evidence indicates that impaired blood coagulation, particularly in serum D-dimer and fibrinogen levels, is a significant complication in patients with COVID-19 that could last for several months. Improving these coagulation indices through training can lead to better and faster recovery in these individuals⁶⁹. Because of this, the full recovery period for individuals with very severe symptoms can take months, and some of them may have experience the disorder for a long time after the infection. Accordingly, physicians believe that the post-recovery period is as important as the period of the disease.^40,70 Blood clots and their complications are concerning for patients with COVID-19. The results indicated a non-significant increase in serum levels of D-dimer and a decrease in fibrinogen during the research period. Mean serum fibrinogen decreased in the training group by 7.9% and 23.1% after 4 and 8 weeks, respectively, while the control group experienced a change of 0.6% and 13.5%. Numerous studies indicated that physical activity does not significantly impact serum fibrinogen levels^71–73. However, some reports have shown a positive correlation between physical activity and fibrinogen levels in various studies involving middle-aged to elderly active and inactive individuals of both genders^74–77. Studies have indicated that the levels of D-dimer can decrease⁷⁸ or increase^79,80 during exercise. In addition, hematological findings from our data showed that the level of WBC and eosinophil in COVID-19 patients were significantly different from those in the control group.

Lowering inflammation levels can enhance sleep quality⁸¹. Hence, regular exercise has the potential to improve both the sleep quality and quality of life. Indeed, many studies have shown that exercise improves sleep quality⁸². After 8 weeks of exercise, the sleep quality of the training group showed a greater improvement compared to the control group, but these changes were not statistically significant. The PSQI in the training group decreased by 33.9% after eight weeks, while the control group experienced a 17.2% decrease. A decrease in PSQI indicates an increase in sleep quality. These findings are supported by studies showing a lack of significant association between exercise and sleep quality in different patients, such as those with lymphoma and cancer^83–85. Additionally, the findings indicate a non-significant increase in the quality of life in the training group. Various studies have demonstrated that exercise has a positive impact on quality of life^82,86. The present study demonstrated that short-term exercise has no significant effect on individuals in the recovery period.

One significant issues with COVID-19 is the decrease in aerobic endurance and cardiorespiratory fitness caused by lung infection, which can result in reduced physical function. Physical dysfunction, fatigue, and muscle weakness are common complaints among patients with COVID-19. Our results demonstrated that aerobic fitness and muscle endurance of patients can increase significantly in response to exercise. The positive effect of physical activity on muscle endurance is highlighted by previous studies^87,88. Therefor the negative effects of COVID-19 on physical fitness may be mitigated by regular training.

Researchers of the current study encountered several limitations during this project. The most challenging task was the eligibility assessment and continues monitoring of participants’ progress throughout the study. The lack of access to a CT scanner limited the accurate assessment of participants’ conditions. With CT scans, the results of this study could be better discussed in relation to different stages of the disease.

Early diagnosis of COVID-19 in crucial in reducing the morbidity and mortality rates and preventing further spread of the disease. It has been reported that CT scans have higher sensitivity in diagnosing COVID-19 than other methods such as PCR⁸⁹. With a lung CT scan, physicians can accurately determine the extent of lung involvement at various stages of COVID-19 infection, providing a more precise assessment of the patient’s health condition than the PCR test⁹⁰. Perhaps future researchers should consider using more advanced technologies to provide objective assessments of patients.

Conclusion

This study evaluated the effects of training during the recovery period on coagulating factors, inflammation, physical fitness, sleep quality, and quality of life indices in patients recovering from COVID-19. The results suggest that 8 weeks of training can improve the physical condition of COVID-19 patients by enhancing the inflammatory state, coagulation system, and sleep quality, thereby helping patients return to normal conditions more quickly. As the first study to implement exercise intervention for people recovering from COVID-19, this research provides a foundation for developing practical and safe recovery methods for COVID-19 patients.

Author contributions

S.B. and M.R. Prepared the original draft, performed the experiments, supervised the training sessions, collected and analyzed the data. H.R., D.G., M.K., R.R., and A.A. Designed Methodology, controlled and supervised the stages of the study and revised the manuscript.

Funding

No sources of funding were sought or awarded for this study.

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare no competing interests.